Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk

Labcorp has several ongoing and completed clinical studies that highlight the clinical utility of Labcorp Plasma Detect to track early disease progression, predict long-term outcomes, and identify residual cancer. Two peer- reviewed publications recently featured clinical studies of Labcorp Plasma Detect that focus on the test's utility in patients diagnosed with diffuse pleural mesothelioma and head and neck cancer, adding to a growing body of research that supports MRD testing as a critical component of p ...